- Investor's Business Daily•yesterday
Ariad had to put off requests from a potential suitor in order to lock in an increased buyout offer from Takeda Pharmaceuticals.
- American City Business Journals•yesterday
Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals on Jan. 9 valued the Cambridge cancer drug firm at $24 per share, a 75 percent premium over its previous closing stock price. A federal filing by Ariad (ARIA) on Thursday includes a lengthy play-by-play of the negotiations, beginning with a phone call on Dec. 2 between Ariad CEO Paris Panayiotopoulos and Takeda CEO Christophe Weber. During the call, Panayiotopoulos told Weber that if Takeda was interested in making a “broader” deal, it should do so in writing, according to the filing.
- Investor's Business Daily•2 days ago
Biotechs have a lot riding on drug data in 2017 with nearly two dozen firms reporting data in four key segments.
ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance